Compare AbCellera Biologics Inc (ABCL) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

SCHG, the Schwab U.S. Large-Cap Growth ETF, trades at $34.53, up 1.2% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology, with top holdings like Nvidia, Apple, and Microsoft. Recent news highlights its positioning to benefit from AI-driven capital expenditure growth, though some analysts note concentration risks.

The outlook for SCHG is supported by strong AI adoption trends and institutional inflows, but risks include high portfolio concentration and sensitivity to interest rate changes. Valuation remains elevated, with a portfolio P/E around 32x, which could pressure returns if growth expectations moderate. Investors should weigh the growth potential against these concentration and macroeconomic risks.